Ekene Emmanuel Nweke
Overview
Explore the profile of Ekene Emmanuel Nweke including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
64
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Pillay K, Khan Z, Nweke E, Omoshoro-Jones J
World J Hepatol
. 2025 Jan;
16(12):1417-1428.
PMID: 39744201
Background: Hepatic abscesses represent infections of the liver parenchyma from bacteria, fungi, and parasitic organisms. Trends in both abscess microbiology and management of abscesses (infective collections) have changed over the...
2.
Elebo N, Abdel-Shafy E, Omoshoro-Jones J, Nsingwane Z, Hussein A, Smith M, et al.
BMC Cancer
. 2024 Jul;
24(1):809.
PMID: 38973003
Background: Pancreatic Ductal Adenocarcinoma (PDAC) is an aggressive cancer characterized by an immunosuppressive microenvironment. Patients from specific ethnicities and population groups have poorer prognoses than others. Therefore, a better understanding...
3.
Elebo N, Mpinganjira M, Baichan P, Devar J, Omoshoro-Jones J, Francis J, et al.
Transl Oncol
. 2024 Jun;
47:102036.
PMID: 38878612
Introduction: Hepatopancreatobiliary (HPB) cancers encompassing malignancies of the liver, pancreas, gall bladder, and bile ducts pose a significant health burden in Africa. While the association of certain occupational carcinogens in...
4.
Elebo N, Abdel-Shafy E, Cacciatore S, Nweke E
Front Genet
. 2023 Oct;
14:1170571.
PMID: 37790705
Pancreatic Ductal Adenocarcinoma (PDAC) is a very lethal disease that typically presents at an advanced stage and is non-compliant with most treatments. Recent technologies have helped delineate associated molecular subtypes...
5.
Xulu K, Nweke E, Augustine T
Front Genet
. 2023 Sep;
14:1087432.
PMID: 37662839
The burden of breast cancer continues to increase worldwide as it remains the most diagnosed tumor in females and the second leading cause of cancer-related deaths. Breast cancer is a...
6.
Hart B, Patel J, De Maayer P, Nweke E, Bizos D
Microorganisms
. 2023 Jun;
11(6).
PMID: 37375113
The human gastrointestinal tract (GIT) is home to an abundance of diverse microorganisms, and the balance of this microbiome plays a vital role in maintaining a healthy GIT. The obstruction...
7.
Malise T, Nweke E, Takundwa M, Fru P, Thimiri Govinda Raj D
Adv Exp Med Biol
. 2023 May;
1436:167-185.
PMID: 37243923
In the past few years, development of approved drug candidates has improved the disease management of multiple myeloma (MM). However, due to drug resistance, some of the patients do not...
8.
Baichan P, Naicker P, Augustine T, Smith M, Candy G, Devar J, et al.
Clin Proteomics
. 2023 Mar;
20(1):8.
PMID: 36855072
Background: Gallbladder cancer (GBC) is a lethal cancer with a poor prognosis. The lack of specific and sensitive biomarkers results in delayed diagnosis with most patients presenting at late stages...
9.
Mosiane K, Nweke E, Balogun M, Fru P
Polymers (Basel)
. 2023 Jan;
15(2).
PMID: 36679328
Pancreatic cancer (PC) is one of the most aggressive solid malignancies with poor treatment response and low survival rates. Herbal medicines such as betulinic acid (BA) have shown potential in...
10.
Kenmogne V, Nweke E, Takundwa M, Fru P, Thimiri Govinda Raj D
Adv Exp Med Biol
. 2022 Oct;
1410:115-126.
PMID: 36289161
Drug resistance in leukaemia is a major problem that needs to be addressed. Precision medicine provides an avenue to reduce drug resistance through a personalised treatment plan. It has helped...